It's a disease that is most common in people in their 70s, more common in women, and almost never seen below the age of 50.

Professor Xenofon Baraliakos, EULAR president-elect, discusses personalised treatment and other challenges and opportunities ...

Researchers discover how mitochondria not only produce energy but also influence inflammation.

The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval for a subcutaneous ...